McKesson buys RXCrossroads from CVS for $735M

|About: CVS Health Corporation (CVS)|By:, SA News Editor

McKesson (NYSE:MCK) agrees to acquire RxCrossroads, a provider of tailored services to pharmaceutical and biotech manufacturers, from CVS Health (NYSE:CVS) for $735M.

MCK says the acquisition will enhance its existing commercialization solutions for manufacturers of branded, specialty, generic and biosimilar drugs, including hub services, custom pharmacy solutions and third-party logistics.

MCK expects the deal to add ~$0.20 to adjusted per-share earnings by the third year after completion.